Cannabis Ineffective for Most Mental Health Conditions, Major Review Finds

The widely held belief that cannabis offers a therapeutic solution for common mental health conditions is not supported by evidence, according to a comprehensive review published in The Lancet Psychiatry. Despite a global increase in patients turning to cannabis for conditions like anxiety and depression, researchers found “very little evidence for its efficacy” in treating a range of mental health challenges, including anxiety, anorexia nervosa, psychotic disorders, post-traumatic stress disorder, and opioid use disorder.

The Scope of the Review and What it Examined

The analysis, conducted by experts from universities in Australia and England, represents the largest and most comprehensive investigation to date into the use of cannabinoids – therapies derived from cannabis – for both substance misuse and mental health disorders. The review was prompted by the increasing trend of countries, including the US, the UK, Australia, and Canada, legalizing cannabis for medicinal purposes. Researchers analyzed data from 54 randomized controlled trials, encompassing a total of 2,477 participants. The study, detailed here, sought to rigorously assess the claims surrounding cannabis as a mental health treatment.

While some evidence suggests potential benefits in specific areas – reducing dependence on cannabis itself, alleviating symptoms of Tourette syndrome, and improving sleep for those with insomnia – the researchers found no compelling evidence to support its use for common mental illnesses. There was also some indication, based on “low” quality evidence, that cannabis might reduce autistic traits in individuals with autism spectrum disorder.

What the Evidence Doesn’t Show

Crucially, the review found no significant positive effects on outcomes related to anxiety, anorexia nervosa, psychotic disorders, post-traumatic stress disorder, or opioid use disorders. The evidence base was also insufficient to draw firm conclusions about the effectiveness of cannabinoids for attention deficit hyperactivity disorder, bipolar disorder, obsessive compulsive disorder, or tobacco use disorder. Notably, there was a complete lack of evidence regarding the efficacy of medicinal cannabis for treating depression.

“Given the scarcity of evidence, the routine use of cannabinoids for the treatment of mental disorders and substance use disorders is currently rarely justified,” the researchers concluded. This finding challenges the perceptions of many patients and highlights a disconnect between anecdotal experiences and rigorous scientific investigation.

The Rise of Cannabis Clinics and Patient Demand

The findings approach as cannabis clinics are experiencing a surge in patients seeking treatment for mental health conditions. Clinics dispensing cannabis for medical purposes report that anxiety and depression are the most frequently cited reasons for seeking treatment, often alongside chronic pain. This trend underscores the growing public perception of cannabis as a potential remedy for a wide range of ailments. Yet, as Professor Sir Robin Murray of King’s College London points out, this perception may be fueled by industry claims and a lack of critical evaluation.

Murray expressed concern that UK cannabis clinics may be functioning more as “drug dealers for the middle class” than legitimate healthcare providers, capitalizing on patient desperation and misleading them about the benefits of cannabis. This perspective raises important ethical questions about the commercialization of cannabis and the potential for exploitation within the medical cannabis industry.

Industry Response and Ongoing Evaluation

The Cannabis Industry Council, however, disputes the review’s conclusions, asserting that cannabis can effectively relieve symptoms of anxiety and post-traumatic stress. Mike Morgan-Giles, the Council’s chief executive, emphasized the importance of ensuring access to treatment for patients with psychiatric conditions. He cited real-world evidence, including findings from the T21 study, which consistently demonstrates symptom reduction in patients with anxiety and PTSD. He criticized the review as adding “more heat than light” and failing to adequately reflect clinical prescribing practices in the UK.

Recognizing the need for a thorough assessment of the current legal framework, the Advisory Council on the Misuse of Drugs in the UK is currently conducting a review of how the legalization of cannabis-based products in 2018 is functioning, including any unintended consequences. This review will inform future policy decisions and ensure that regulations are aligned with the latest scientific evidence.

What Does This Imply for Patients?

Professor Owen Bowden-Jones, registrar of the Royal College of Psychiatrists, underscored the importance of providing patients with accurate and transparent information about cannabis-based products. He stated that while these products may offer modest benefits for some addictions, they should not be offered for the many mental illnesses for which no benefit was found. This highlights the need for open and honest conversations between clinicians and patients about the potential risks and benefits of cannabis treatment.

The research emphasizes that while cannabis may have a role in managing certain conditions, it is not a panacea for mental health issues. Patients considering cannabis as a treatment option should consult with a qualified healthcare professional to discuss their individual circumstances and explore evidence-based alternatives.

Looking Ahead: Further Research and Policy Adjustments

The findings from this review are likely to prompt further research into the potential therapeutic applications of cannabinoids, as well as a re-evaluation of current policies regarding medical cannabis. Future studies should focus on addressing the limitations of existing research, including the need for larger sample sizes, more rigorous methodologies, and a better understanding of the long-term effects of cannabis use. The ongoing review by the Advisory Council on the Misuse of Drugs will be crucial in shaping the future of cannabis regulation in the UK, ensuring that policies are based on sound scientific evidence and prioritize patient safety.